557 related articles for article (PubMed ID: 18202704)
1. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
2. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
3. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
4. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
Arizono Y; Yoshikawa H; Naganuma H; Hamada Y; Nakajima Y; Tasaka K
Br J Cancer; 2003 Jan; 88(2):298-306. PubMed ID: 12610517
[TBL] [Abstract][Full Text] [Related]
6. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
[TBL] [Abstract][Full Text] [Related]
7. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Rieger J; Frank B; Weller M; Wick W
Cell Physiol Biochem; 2007; 20(1-4):23-34. PubMed ID: 17595512
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
10. Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.
Song T; Zhang M; Wu J; Chen F; Wang Y; Ma Y; Dai Z
Invest New Drugs; 2020 Dec; 38(6):1743-1754. PubMed ID: 32767162
[TBL] [Abstract][Full Text] [Related]
11. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
[TBL] [Abstract][Full Text] [Related]
12. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
13. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells.
Schmidt F; Groscurth P; Kermer M; Dichgans J; Weller M
Acta Neuropathol; 2001 Mar; 101(3):217-24. PubMed ID: 11307620
[TBL] [Abstract][Full Text] [Related]
15. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y
PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160
[TBL] [Abstract][Full Text] [Related]
16. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5.
Kong R; Jia G; Cheng ZX; Wang YW; Mu M; Wang SJ; Pan SH; Gao Y; Jiang HC; Dong DL; Sun B
PLoS One; 2012; 7(5):e37222. PubMed ID: 22666346
[TBL] [Abstract][Full Text] [Related]
17. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
Steinbach JP; Supra P; Huang HJ; Cavenee WK; Weller M
Brain Pathol; 2002 Jan; 12(1):12-20. PubMed ID: 11770895
[TBL] [Abstract][Full Text] [Related]
18. DATS sensitizes glioma cells to TRAIL-mediated apoptosis by up-regulation of death receptor 5 via ROS.
Hwang JS; Lee YY; Lee DH; Kwon KH
Food Chem Toxicol; 2017 Aug; 106(Pt A):514-521. PubMed ID: 28571773
[TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
20. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
